The incidence and mortality of kala-azar (KA, visceral leishmaniasis) in India have fallen drastically in the past few years, and in 2023 the reported KA incidence reached the threshold for elimination as a public health problem (<1 case/10 000 of population at subdistrict level). One of the strategies adopted by India's kala-azar elimination program (KAEP) was the regular independent assessment of the program implementation by teams of experts. We present the findings of assessments undertaken in 2019, 2021 and 2023, when the KAEP was in the last mile of elimination. Factors that contributed to its success were political commitment, intensified implementation, a strong network of KA partners and committed donors. Bottlenecks were observed in disease surveillance, data utilization, vector-control operations and program management at implementation. To sustain the gains and achieve validation of elimination, the KAEP should continue the following minimal essential services: optimized active and passive case detection and management of KA, post-KA dermal leishmaniasis, KA-HIV coinfection and relapse supported by vector-control interventions. Long-term measures that will sustain elimination are overall socioeconomic development, including improved living conditions, parallel with efficient surveillance and operational research that is aligned with the changing epidemiology of the disease.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/inthealth/ihaf013 | DOI Listing |
Int Health
March 2025
Directorate of National Centre for Disease Control, New Delhi 110054, India.
The incidence and mortality of kala-azar (KA, visceral leishmaniasis) in India have fallen drastically in the past few years, and in 2023 the reported KA incidence reached the threshold for elimination as a public health problem (<1 case/10 000 of population at subdistrict level). One of the strategies adopted by India's kala-azar elimination program (KAEP) was the regular independent assessment of the program implementation by teams of experts. We present the findings of assessments undertaken in 2019, 2021 and 2023, when the KAEP was in the last mile of elimination.
View Article and Find Full Text PDFInt J Biol Macromol
February 2025
Department of Molecular Biology, Indian Council of Medical Research - Rajendra Memorial Research Institute of Medical Sciences, Patna 800007, India. Electronic address:
Despite efforts to eliminate Visceral Leishmaniasis (VL) in India, it continues to be a public health issue due to the occurrence of relapse post AmBisome treatment. The role of host genetics in susceptibility of VL relapse is not clearly understood. Here we have performed whole exome sequencing (WES) on healthy, VL relapse and non-relapse individuals.
View Article and Find Full Text PDFBMJ Public Health
June 2024
ICMR-National Institute of Malaria Research, New Delhi, Delhi, India.
Vector-borne diseases (VBDs) exert a substantial burden across the world, especially in tropical countries. Malaria, chikungunya, dengue, visceral leishmaniasis, lymphatic filariasis and Japanese encephalitis are among the public health concerns for India. One of the major pillars for the containment of VBDs is vector control and different tools have been employed for several decades.
View Article and Find Full Text PDFBMC Infect Dis
February 2025
Institute of Tropical Medicine, Antwerp, Belgium.
Background: The ongoing kala-azar elimination program in Nepal is based on the assumption of anthroponotic transmission of the protozoan parasite Leishmania donovani. This parasite species was recently also found in lesions of cutaneous leishmaniasis (CL) cases, which are increasingly reported mainly from western Nepal. The question whether or not CL causing L.
View Article and Find Full Text PDFPLoS Negl Trop Dis
February 2025
Novartis Pharma A.G., Basel, Switzerland.
Background: Visceral leishmaniasis (VL) is a vector-borne disease caused by Leishmania parasites and transmitted by sand fly bites, targeted for elimination in India. VL primarily affects rural, low-income populations with limited health care access. In South Asia, few studies have explored patients' perspectives, diagnoses, and treatment experiences; particularly lacking an understanding about the patients' life experiences outside of clinical research settings.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!